Letrozole for hormone receptor–positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial

Abstract

Background:

Epidemiological and retrospective studies suggest that letrozole may improve outcomes in low-grade serous carcinoma of the ovary (LGSCO) by targeting estrogen-driven tumor progression.

Methods:

We designed a multicenter, randomized, open-label, phase III trial to compare letrozole versus standard chemotherapy (carboplatin plus paclitaxel) in prolonging progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), quality of life (MENQoL), and musculoskeletal pain (BPI-SF). Translational objectives explore mutational and expression profiles (NGS, RAD51/BRCA1 foci) and circulating tumor DNA (ctDNA) as markers of treatment response. Eligible patients are postmenopausal women with stage III–IV ER/PgR-positive LGSCO after primary cytoreductive surgery. Patients are randomized 1:1 to letrozole 2.5 mg daily until progression or unacceptable toxicity, or to carboplatin-paclitaxel for 6–8 cycles. Disease progression is assessed by RECIST, CA-125, and imaging every 3–6 months.

Results:

As of March 2025, 46 patients have been randomized (23 per arm). Preliminary analysis shows a favorable safety profile for letrozole compared with chemotherapy.

Conclusions:

Early findings suggest letrozole is well tolerated and may represent a viable therapeutic option for hormone receptor-positive LGSCO. Ongoing molecular and clinical analyses will clarify its role in this rare subtype.

Trial registration:

ClinicalTrials.gov Identifier: NCT05601700; https://clinicaltrials.gov/study/NCT05601700

Keywords

letrozole ovarian cancer low-grade serous carcinoma hormone receptor phase III trial endocrine therapy

Get full access to this article

View all access options for this article.

References

Gershenson

Sun

, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obst Gynecol 2006; 108: 361–368.

Ozols

Bundy

Greer

, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. JCO 2003; 21: 3194–3200.

Gourley

Farley

Provencher

D.M.

Pignata

Mileshkin

Harter

Maenpaa

Kim

J.-W

Pujaide-Lauraine

Glasspool

R.M

, et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas. Int J Gynecol Cancer 2014; 24: S9–S13.

Baak

Delemarre

Langley

, et al. Grading ovarian tumors. Evaluation of decision making by different pathologists. Anal Quant Cytol Histol 1986 Dec;8(4): 349–353. PMID: 3814302.

Stalsberg

Abeler

Blom

, et al. Observer variation in histologic classification of malignant and borderline ovarian tumors. Human Pathol 1988; 19: 1030–1035.

Bertelsen

HØLund

Andersen

. Reproducibility and prognostic value of histologic type and grade in early epi-thelial ovarian cancer. Int J Gynecol Cancer 1993; 3: 72–79.

Shimizu

Kamoi

Amada

, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998; 82: 893–901.

Ishioka

Sagae

Terasawa

, et al. Comparison of the usefulness be-tween a new universal grading system for epithelial ovarian cancer and the FIGO grading system. Gynecol Oncol 2003; 89: 447–452.

Seidman

Horkayne-Szakaly

Cosin

, et al. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol 2006; 103: 703–708.

10.

Bonome

Lee

J-Y

Park

D-C

, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005; 65: 10602–10612.

11.

Jazaeri

Schmandt

, et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Molec Carcinogen 2003; 36: 53–59.

12.

Meinhold-Heerlein

Bauerschlag

Hilpert

, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005; 24: 1053–1065.

13.

Sieben

Macropoulos

Roemen

, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004; 202: 336–340.

14.

Singer

Oldt

Cohen

, et al. Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma. JNCI 2003; 95: 484–486.

15.

Orphanet: The portal for rare diseases and orphan drugs. Available at: https://www.orpha.net.

16.

National Center for Advancing Translational Sciences (NCATS). Available at: https://ncats.nih.gov/.

17.

Gershenson

Bodurka

, et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. JCO 2015; 33: 2675–2682.

18.

Wong

K-K

Tsang

YTM

Deavers

, et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 2010; 177: 1611–1617.

19.

Grisham

Iyer

Garg

, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013; 119: 548–554.

20.

Schmeler

Sun

Bodurka

, et al. Neo-adjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008; 108: 510–514.

21.

Gershenson

Sun

Bodurka

, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 2009; 114: 48–52.

22.

Schmeler

Sun

Malpica

, et al. Low-grade serous primary peritoneal carcinoma. Gynecol Oncol 2011; 121: 482–486.

23.

Grabowski

Harter

Heitz

, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO study group metadatabase. Gynecol Oncol 2016; 140: 457–462.

24.

Bookman

Brady

McGuire

, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the gynecologic cancer InterGroup. JCO 2009; 27: 1419–1425.

25.

Gershenson

Bodurka

Coleman

, et al. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. JCO 2017; 35: 1103–1111.

26.

Wong

K-K

Malpica

, et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 2007; 26: 404–409.

27.

Escobar

Klimowicz

Dean

, et al. Quantification of ER/PR expression in ovarian low-grade serous carcinoma. Gynecol Oncol 2013; 128: 371–376.

28.

Ahmad Fauzi

Wan Ahmad

WSHM

Jamaluddin

, et al. Allred scoring of ER-IHC stained whole-slide images for hormone receptor status in breast carcinoma. Diagnostics (Basel) 2022; 12: 3093.

29.

Fader

, et al. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? Gynecol Oncol. 2017 Oct;147(1):85–91.

30.

McLaughlin

PMJ

Klar

Zwimpfer

, et al. Maintenance therapy with aromatase inhibitor in epithelial ovarian cancer (MATAO): Study protocol of a randomized double-blinded placebo-controlled multi-center phase III trial. BMC Cancer 2022; 22: 508.

31.

Cobb

Davis

Hull

, et al. A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma. J Clin Oncol. 2022;40(16_suppl):5522.

32.

Grisham

Slomovitz

Andrews

, et al. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer 2023: 33: 1331–1344.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.24 MB